Journal of Nephrology

, Volume 30, Issue 6, pp 851–857 | Cite as

De novo cancer in patients on dialysis and after renal transplantation: north-western Italy, 1997–2012

  • Valentina Mazzucotelli
  • Pierluca Piselli
  • Diana Verdirosi
  • Claudia Cimaglia
  • Giovanni Cancarini
  • Diego Serraino
  • Silvio Sandrini
Original Article



Kidney transplant recipients (KTR) are known to have a higher risk of cancer than the general population, especially of malignancies related to oncogenic viral infections. This study assessed the incidence of de novo malignancies (DNMs) in patients receiving kidney transplantation and in dialysis patients (DP) on the waiting list for transplantation at the same centre. The aim was to quantify the contribution of post-transplant immunosuppression to the underlying risk of developing a DNM in dialysis patients on the waiting list for kidney transplant.


Cancer incidence rates were computed using the Kaplan–Meier product-limit method. The number of DNMs observed in both groups was compared to the expected incidence in the general Italian population through calculation of the standardized incidence ratios (SIR) and their 95% confidence intervals (CI). To identify risk factors, incidence rate ratios (IRR) and 95% CIs were computed using Poisson regression analysis. The comparison of incidence rates between the two cohorts was also performed using age standardized incidence rates (ASR) and their ratio (age standardized rate ratio, ASRR).


In 4858 person-years (PYs) of observation, 75 out of 735 KTR were diagnosed with DNM: 57 solid neoplasms, 13 post-transplant lymphoproliferative disorders (PTLD), and 12 Kaposi sarcomas (KS). The overall incidence was 17.5 cases/103 PYs, resulting in a 2.1-fold increased risk. Twenty-four out of 912 DP, over a follow-up of 2400 PYs, were diagnosed with a solid neoplasm, but none had PTLD or KS. The use of induction therapy after transplant was associated with a significant increased risk of KS (IRR: 3.52; 95% CI 1.04–11.98, p < 0.05). ASRR for all cancers and for solid cancers only was 1.84- and 1.19-fold higher in KTR, respectively, than in the general population. The overall incidence in DP was 10.0 cases/103 PYs, with a 1.6 significantly increased cancer risk compared to the general population.


Our study confirms the increased risk of cancer after transplantation and during dialysis, but showed that virus-related cancers only occur after post-transplant immunosuppression.


Kidney transplantation Immunosuppression Cancer risk Oncogenic viruses Dialysis 



This study was supported by the “Associazione Italiana per la Ricerca sul Cancro-AIRC, Milan, Italy”; Ministero della Salute, Ricerca Finalizzata and Programma di Ricerca Corrente IRCCS INMI Spallanzani, Rome, Italy and IRCCS Centro di Riferimento Oncologico, Aviano (PN), Italy.

Compliance with ethical standards

Conflict of interest

None of the authors declare conflict of interest.

Ethical approval

The study was approved in 2012 by the Ethical Committee of Centro di Riferimento Oncologico di Aviano, the Institution of the PI of the overall research proposal.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Buell JF, Gross TG, Woodle S (2005) Malignancy after transplantation. Transplantation 80:S254–S264CrossRefPubMedGoogle Scholar
  2. 2.
    Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M (2004) Malignancy in renal transplantation. J Am Soc Nephrol 15:1582–1588CrossRefPubMedGoogle Scholar
  3. 3.
    Piselli P, Busnach G, Fratino L et al (2013) De Novo malignancies after organ transplantation: focus on viral infections. Curr Mol Med 13:1217–1227CrossRefPubMedGoogle Scholar
  4. 4.
    Ponticelli C, Cucchiari D, Bencini P (2014) Skin cancer in kidney transplant recipients. J Nephrol 27:385–394CrossRefPubMedGoogle Scholar
  5. 5.
    Piselli P, Serraino D, Segoloni GP et al (2013) Risk of de novo cancer after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009. Eur J Cancer 49:336–344CrossRefPubMedGoogle Scholar
  6. 6.
    World Health Organization. 1992. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, GenevaGoogle Scholar
  7. 7.
    Goodwin RG, Holme SA, Roberts DL (2004) Variation of registration of skin cancer in the United Kingdom. Clin Exp Dermatol 29:328–330CrossRefPubMedGoogle Scholar
  8. 8.
    Breslow NE, Day NE (1987) The design and analysis of cohort studies. In: Heseline E (ed) Statistical methods in cancer research. International Agency for Research on Cancer Scientific Publications, Lyon, pp 2–391Google Scholar
  9. 9.
    Curado MP, Edwards B, Shin HR et al (2007) Cancer Incidence in Five Continents, vol. IX. IARC Sci Publ No. 160. IARC Press, LyonGoogle Scholar
  10. 10.
    AIRTUM, ITACAN (2017) Cancer in Italy, Version 2.0. Italian Association of Cancer Registries (
  11. 11.
    Cislaghi C (2009) Effective and effortless data standardization. Epidemiol Prev 33:190–192PubMedGoogle Scholar
  12. 12.
    Maissonneuve P, Agodoa L, Gellert R et al (1999) Cancer in patient on dialysis for end-stage renal disease: an international collaborative study. Lancet 354:93–99CrossRefGoogle Scholar
  13. 13.
    Birkeland SA, Løkkegaard H, Storm HH (2000) Cancer risk in patients on dialysis and after renal transplantation. Lancet 355:1886–1887CrossRefPubMedGoogle Scholar
  14. 14.
    Vajdic CM, McDonald SP, McCredie MRE et al (2006) Cancer incidence before and after kidney transplantation. JAMA 296:2823–2831CrossRefPubMedGoogle Scholar
  15. 15.
    Centro Nazionale Trapianti; Accessed 8 Mar 2017
  16. 16.
    Van Leeuwen MT, Webster AC, McCredie MR et al (2010) Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 340:c570CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Van Leeuwen MT, Grulich AE, McDonald SP et al (2009) Immunosuppression and other risk factors for lip cancer after kidney transplantation. Cancer Epidemiol Biomark Prev 18:561–569CrossRefGoogle Scholar
  18. 18.
    Opelz G, Döhler B (2004) Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4:222–230CrossRefPubMedGoogle Scholar
  19. 19.
    Hosseini-Moghaddam SM, Soleimanirahbar A, Mazzulli T, Rotstein C, Husain S (2012) Post renal transplantation Kaposi’s sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy. Transpl Infect Dis 14:338–345CrossRefPubMedGoogle Scholar
  20. 20.
    Lowrance WT, Ordoñez J, Udaltsova N, Russo P, Go AS (2014) CKD and the risk of incident cancer. J Am Soc Nephrol 25:2327–2334CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Frascà GM, Sandrini S, Cosmai L et al (2015) Renal cancer in kidney transplanted patients. J Nephrol 28:659–668CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Nephrology 2017

Authors and Affiliations

  1. 1.Operative Unit of NephrologyASST Spedali CiviliBresciaItaly
  2. 2.Clinical Epidemiology Unit - Department of Epidemiology and Preclinical ResearchNational Institute for Infectious Diseases “L. Spallanzani” IRCCSRomeItaly
  3. 3.Unit of Cancer EpidemiologyCRO Aviano National Cancer Institute, IRCCSAviano (PN)Italy
  4. 4.School of MedicineUniversity of BresciaBresciaItaly

Personalised recommendations